Vertex Pharmaceuticals | VRTX - Sales Revenues

Stock Price
427.25
Daily Change
4.01 0.95%
Monthly
-4.32%
Yearly
-14.35%
Q2 Forecast
421.08

Vertex Pharmaceuticals reported $3.19B in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Acadia Pharmaceuticals USD 284M 5.4M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
Arrowhead Research USD 264.03M 7.56M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 875M 99M Dec/2025
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Gilead Sciences USD 7.93B 130M Dec/2025
Incyte USD 1.27B 240M Mar/2026
Insmed USD 263.8M 121.8M Dec/2025
Ionis Pharmaceuticals USD 246M 43M Mar/2026
J&J USD 24.1B 500M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 678M 342M Dec/2025
Neurocrine Biosciences USD 805.5M 10.6M Dec/2025
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 17.58B 880M Dec/2025
PTC Therapeutics USD 164.7M 46.3M Dec/2025
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
Sangamo BioSciences USD 356K 125K Jun/2024
Sanofi EUR 11.24B 60M Mar/2026
Sarepta Therapeutics USD 442.9M 43.5M Dec/2025
Ultragenyx Pharmaceutical USD 207M 47M Dec/2025
United Therapeutics USD 790.2M 9.3M Dec/2025
Vertex Pharmaceuticals USD 3.19B 110M Dec/2025